Monash University researchers alongside key partner Halozyme Therapeutics have reported findings in support of shifting the way anti-cancer ...
The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
Monash University researchers alongside key partner Halozyme Therapeutics have reported findings in support of shifting the way anti-cancer ...
The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...
Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...
For anyone managing bipolar 1 disorder, staying consistent with daily medication can be a challenge. Busy schedules, shifting moods, and side effects can make it easy to miss doses — and even brief ...
New LEQEMBI Companion TM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an ...
Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope. Although the combination of amivantamab plus ...
The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results